U.S. markets open in 3 hours 35 minutes
  • S&P Futures

    3,628.25
    -4.50 (-0.12%)
     
  • Dow Futures

    29,937.00
    -61.00 (-0.20%)
     
  • Nasdaq Futures

    12,106.50
    +30.50 (+0.25%)
     
  • Russell 2000 Futures

    1,847.60
    -3.90 (-0.21%)
     
  • Crude Oil

    45.50
    +0.59 (+1.31%)
     
  • Gold

    1,806.70
    +2.10 (+0.12%)
     
  • Silver

    23.41
    +0.11 (+0.47%)
     
  • EUR/USD

    1.1905
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    0.8820
    0.0000 (0.00%)
     
  • Vix

    21.92
    -0.74 (-3.27%)
     
  • GBP/USD

    1.3317
    -0.0041 (-0.31%)
     
  • USD/JPY

    104.4320
    -0.0480 (-0.05%)
     
  • BTC-USD

    19,215.59
    +361.60 (+1.92%)
     
  • CMC Crypto 200

    381.74
    +11.98 (+3.24%)
     
  • FTSE 100

    6,408.80
    -23.37 (-0.36%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

ChemoCentryx: 3Q Earnings Snapshot

·1 min read

MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Monday reported a loss of $24.1 million in its third quarter.

The Mountain View, California-based company said it had a loss of 35 cents per share.

The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 28 cents per share.

The biopharmaceutical company posted revenue of $5.1 million in the period, also missing Street forecasts. Five analysts surveyed by Zacks expected $12.9 million.

ChemoCentryx shares have increased 47% since the beginning of the year. In the final minutes of trading on Monday, shares hit $57.98, climbing fivefold in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI